|Selective inhibition of BET bromodomains|
P Filippakopoulos, J Qi, S Picaud, Y Shen, WB Smith, O Fedorov, ...
Nature 468 (7327), 1067-1073, 2010
|Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination|
M Vedadi, FH Niesen, A Allali-Hassani, OY Fedorov, PJ Finerty, ...
Proceedings of the National Academy of Sciences 103 (43), 15835-15840, 2006
|NMR-based model of a telomerase-inhibiting compound bound to G-quadruplex DNA|
OY Fedoroff, M Salazar, H Han, VV Chemeris, SM Kerwin, LH Hurley
Biochemistry 37 (36), 12367-12374, 1998
|A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases|
O Fedorov, B Marsden, V Pogacic, P Rellos, S Müller, AN Bullock, ...
Proceedings of the National Academy of Sciences 104 (51), 20523-20528, 2007
|Structure of a DNA: RNA hybrid duplex: why RNase H does not cleave pure RNA|
OY Fedoroff, M Salazar, BR Reid
Journal of molecular biology 233 (3), 509-523, 1993
|G-quadruplexes as targets for drug design|
LH Hurley, RT Wheelhouse, D Sun, SM Kerwin, M Salazar, OY Fedoroff, ...
Pharmacology & therapeutics 85 (3), 141-158, 2000
|RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain|
S Picaud, C Wells, I Felletar, D Brotherton, S Martin, P Savitsky, ...
Proceedings of the National Academy of Sciences 110 (49), 19754-19759, 2013
|The (un) targeted cancer kinome|
O Fedorov, S Müller, S Knapp
Nature chemical biology 6 (3), 166-169, 2010
|Dual kinase-bromodomain inhibitors for rationally designed polypharmacology|
P Ciceri, S Müller, A O'mahony, O Fedorov, P Filippakopoulos, JP Hunt, ...
Nature chemical biology 10 (4), 305-312, 2014
|Induction of duplex to G-quadruplex transition in the c-myc promoter region by a small molecule|
A Rangan, OY Fedoroff, LH Hurley
Journal of Biological Chemistry 276 (7), 4640-4646, 2001
|PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains|
S Picaud, D Da Costa, A Thanasopoulou, P Filippakopoulos, PV Fish, ...
Cancer research 73 (11), 3336-3346, 2013
|Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains|
DA Hay, O Fedorov, S Martin, DC Singleton, C Tallant, C Wells, S Picaud, ...
Journal of the American Chemical Society 136 (26), 9308-9319, 2014
|Structural analysis identifies imidazo [1, 2-b] pyridazines as PIM kinase inhibitors with in vitro antileukemic activity|
V Pogacic, AN Bullock, O Fedorov, P Filippakopoulos, C Gasser, A Biondi, ...
Cancer research 67 (14), 6916-6924, 2007
|3, 5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands|
DS Hewings, M Wang, M Philpott, O Fedorov, S Uttarkar, ...
Journal of medicinal chemistry 54 (19), 6761-6770, 2011
|The DNA strand in DNA. cntdot. RNA hybrid duplexes is neither B-form nor A-form in solution|
M Salazar, OY Fedoroff, JM Miller, NS Ribeiro, BR Reid
Biochemistry 32 (16), 4207-4215, 1993
|Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit|
PV Fish, P Filippakopoulos, G Bish, PE Brennan, ME Bunnage, AS Cook, ...
Journal of medicinal chemistry 55 (22), 9831-9837, 2012
|Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase|
AN Bullock, JÉ Debreczeni, OY Fedorov, A Nelson, BD Marsden, S Knapp
Journal of medicinal chemistry 48 (24), 7604-7614, 2005
|Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing|
O Fedorov, K Huber, A Eisenreich, P Filippakopoulos, O King, AN Bullock, ...
Chemistry & biology 18 (1), 67-76, 2011
|Structural diversity in the RGS domain and its interaction with heterotrimeric G protein α-subunits|
M Soundararajan, FS Willard, AJ Kimple, AP Turnbull, LJ Ball, GA Schoch, ...
Proceedings of the National Academy of Sciences 105 (17), 6457-6462, 2008
|Design and synthesis of fluoroquinophenoxazines that interact with human telomeric g-quadruplexes and their biological effects1|
W Duan, A Rangan, H Vankayalapati, MY Kim, Q Zeng, D Sun, H Han, ...
Molecular cancer therapeutics 1 (2), 103-120, 2001